Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2737
Abstract: The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF patients treated with ruxolitinib, we investigated incidence and risk factors for BP and… read more here.
Keywords: risk; blast phase; treated ruxolitinib; myelofibrosis ... See more keywords
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3569-1
Abstract: Comorbidities defined by the Charlson comorbidity index (CCI) and body mass index (BMI) are significantly associated with outcome in patients who receive continuous treatment with tyrosine kinase inhibitors. We evaluated the impact of CCI and… read more here.
Keywords: index; body mass; hematology; treated ruxolitinib ... See more keywords
A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib
Sign Up to like & getrecommendations! Published in 2019 at "BMC Infectious Diseases"
DOI: 10.1186/s12879-019-3922-6
Abstract: BackgroundRuxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation. However new reports are also emerging that suggest greater immunosuppression and risk for fungal… read more here.
Keywords: treated ruxolitinib; histoplasmosis concurrent; disseminated histoplasmosis; case ... See more keywords